The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue‐type plasminogen activator

Plasminogen activators (tPA and uPA) are serine proteases that convert the circulating zymogen plasminogen to active plasmin and mediate fibrin degradation. These multifunctional proteins trigger various biological events such as extracellular matrix degradation, cell adhesion, migration, and prolif...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The FASEB journal 2004-09, Vol.18 (12), p.1398-1400
Hauptverfasser: Maupas‐Schwalm, Françoise, Augé, Nathalie, Robinet, Catherine, Cambus, Jean‐Pierre, Parsons, Sarah J., Salvayre, Robert, Nègre‐Salvayre, Anne
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1400
container_issue 12
container_start_page 1398
container_title The FASEB journal
container_volume 18
creator Maupas‐Schwalm, Françoise
Augé, Nathalie
Robinet, Catherine
Cambus, Jean‐Pierre
Parsons, Sarah J.
Salvayre, Robert
Nègre‐Salvayre, Anne
description Plasminogen activators (tPA and uPA) are serine proteases that convert the circulating zymogen plasminogen to active plasmin and mediate fibrin degradation. These multifunctional proteins trigger various biological events such as extracellular matrix degradation, cell adhesion, migration, and proliferation, through not yet fully characterized mechanisms. We report that, in smooth muscle cells and ECV‐304 carcinoma cells, tPA and ATF (the N‐terminal catalytically inactive fragment of tPA) elicited DNA synthesis that requires activation of the sphingomyelin/ceramide/sphingosine‐1‐phosphate (Spm/Cer/S1P), signaling pathway and was blocked by D‐erythro‐2‐(N‐myristoylamino)‐1‐phenyl‐propanol (D‐MAPP) and N‐N’‐dimethyl sphingosine (DMS), two classical inhibitors of sphingosine‐1‐phosphate biosynthesis. Binding of tPA to its receptor uPAR triggered the coordinated activation of two key enzymes of the Spm/Cer/S1P pathway, the neutral sphingomyelinase and the sphingosine kinase‐1 that was mediated by a common pertussis toxin (PTX)‐sensitive mechanism. The tPA‐induced sphingosine kinase‐1 activation was mediated by Src, since it was inhibited by herbimycin A and in SrcK‐cells (overexpressing a dominant negative kinase defective form of Src) and by ERK1/2 (early phase peaking at 15 min). Sphingosine kinase‐1 activation was followed by a second phase of ERK1/2 phosphorylation (peaking at 120 min) and subsequent DNA synthesis, which were inhibited by D‐MAPP and DMS, by anti‐EGD‐1 antibodies and in SrcK‐cells (in which the mitogenic signaling was rescued by sphingosine‐1‐phosphate). Altogether, these data underline a pivotal role for the Spm/Cer/S1P pathway in the tPA‐induced mitogenic signaling.
doi_str_mv 10.1096/fj.03-1123fje
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66822120</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66822120</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406E-5e77344c75c997435727a9188206553e614c801cf6f66069a740cc896513f68a3</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EokvhyBX5xIl0x3biJNxKtVsolUClnCPXGXe9cuJgJ1ty4xH6EDwZT4JXuxI3Th7b33yj0U_IawZnDGq5NNszEBljXJgtPiELVgjIZCXhKVlAVfNMSlGdkBcxbgGAAZPPyQkruGAlzxfk9-0GaRw2tr_33YzO9kuNQXW2RTqocfOgZmojtf3Oux22qaCrm89syemw8anPh9mp0fr-HdXoHB2Cd9Ykw-FN9S2dvp7fUL_DgD-HgDGmj6RpJ510dzMdbYwT_vn1OM5DmulU7Gzv77GnSo92p0YfXpJnRrmIr47nKfm-Xt1efMyuv1x-uji_znQOcpUVWJYiz3VZ6Louc1GUvFQ1qyoOsigESpbrCpg20kgJslZlDlpXtSyYMLJS4pS8PXjTFj8mjGPT2bhfS_Xop9hIWXHOOCQwO4A6-BgDmmYItlNhbhg0-1gas21ANMdYEv_mKJ7uOmz_0cccEvD-ADxYh_P_bc362we-vgKxv6-vVuIvFfaeWg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66822120</pqid></control><display><type>article</type><title>The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue‐type plasminogen activator</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Maupas‐Schwalm, Françoise ; Augé, Nathalie ; Robinet, Catherine ; Cambus, Jean‐Pierre ; Parsons, Sarah J. ; Salvayre, Robert ; Nègre‐Salvayre, Anne</creator><creatorcontrib>Maupas‐Schwalm, Françoise ; Augé, Nathalie ; Robinet, Catherine ; Cambus, Jean‐Pierre ; Parsons, Sarah J. ; Salvayre, Robert ; Nègre‐Salvayre, Anne</creatorcontrib><description>Plasminogen activators (tPA and uPA) are serine proteases that convert the circulating zymogen plasminogen to active plasmin and mediate fibrin degradation. These multifunctional proteins trigger various biological events such as extracellular matrix degradation, cell adhesion, migration, and proliferation, through not yet fully characterized mechanisms. We report that, in smooth muscle cells and ECV‐304 carcinoma cells, tPA and ATF (the N‐terminal catalytically inactive fragment of tPA) elicited DNA synthesis that requires activation of the sphingomyelin/ceramide/sphingosine‐1‐phosphate (Spm/Cer/S1P), signaling pathway and was blocked by D‐erythro‐2‐(N‐myristoylamino)‐1‐phenyl‐propanol (D‐MAPP) and N‐N’‐dimethyl sphingosine (DMS), two classical inhibitors of sphingosine‐1‐phosphate biosynthesis. Binding of tPA to its receptor uPAR triggered the coordinated activation of two key enzymes of the Spm/Cer/S1P pathway, the neutral sphingomyelinase and the sphingosine kinase‐1 that was mediated by a common pertussis toxin (PTX)‐sensitive mechanism. The tPA‐induced sphingosine kinase‐1 activation was mediated by Src, since it was inhibited by herbimycin A and in SrcK‐cells (overexpressing a dominant negative kinase defective form of Src) and by ERK1/2 (early phase peaking at 15 min). Sphingosine kinase‐1 activation was followed by a second phase of ERK1/2 phosphorylation (peaking at 120 min) and subsequent DNA synthesis, which were inhibited by D‐MAPP and DMS, by anti‐EGD‐1 antibodies and in SrcK‐cells (in which the mitogenic signaling was rescued by sphingosine‐1‐phosphate). Altogether, these data underline a pivotal role for the Spm/Cer/S1P pathway in the tPA‐induced mitogenic signaling.</description><identifier>ISSN: 0892-6638</identifier><identifier>EISSN: 1530-6860</identifier><identifier>DOI: 10.1096/fj.03-1123fje</identifier><identifier>PMID: 15231724</identifier><language>eng</language><publisher>United States: Federation of American Societies for Experimental Biology</publisher><subject>Benzoquinones ; Cell Line ; Cell Proliferation - drug effects ; Ceramides - metabolism ; Enzyme Activation - drug effects ; Extracellular Signal-Regulated MAP Kinases - metabolism ; Lactams, Macrocyclic ; Lysophospholipids - pharmacology ; MAP Kinase Signaling System - drug effects ; Mitogens - pharmacology ; Myocytes, Smooth Muscle - cytology ; Myocytes, Smooth Muscle - drug effects ; Myocytes, Smooth Muscle - enzymology ; Myocytes, Smooth Muscle - metabolism ; Peptide Fragments - chemistry ; Peptide Fragments - pharmacology ; Pertussis Toxin - pharmacology ; Phosphorylation - drug effects ; Phosphotransferases (Alcohol Group Acceptor) - metabolism ; Quinones - pharmacology ; Rifabutin - analogs &amp; derivatives ; Signal Transduction - drug effects ; Sphingomyelins - metabolism ; Sphingosine - analogs &amp; derivatives ; Sphingosine - pharmacology ; sphingosine kinase ; Src ; Tissue Plasminogen Activator - pharmacology ; tPA ; Up-Regulation - drug effects ; Urokinase-Type Plasminogen Activator - chemistry ; Urokinase-Type Plasminogen Activator - genetics ; Urokinase-Type Plasminogen Activator - pharmacology</subject><ispartof>The FASEB journal, 2004-09, Vol.18 (12), p.1398-1400</ispartof><rights>FASEB</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406E-5e77344c75c997435727a9188206553e614c801cf6f66069a740cc896513f68a3</citedby><cites>FETCH-LOGICAL-c406E-5e77344c75c997435727a9188206553e614c801cf6f66069a740cc896513f68a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1096%2Ffj.03-1123fje$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1096%2Ffj.03-1123fje$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27931,27932,45581,45582</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15231724$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maupas‐Schwalm, Françoise</creatorcontrib><creatorcontrib>Augé, Nathalie</creatorcontrib><creatorcontrib>Robinet, Catherine</creatorcontrib><creatorcontrib>Cambus, Jean‐Pierre</creatorcontrib><creatorcontrib>Parsons, Sarah J.</creatorcontrib><creatorcontrib>Salvayre, Robert</creatorcontrib><creatorcontrib>Nègre‐Salvayre, Anne</creatorcontrib><title>The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue‐type plasminogen activator</title><title>The FASEB journal</title><addtitle>FASEB J</addtitle><description>Plasminogen activators (tPA and uPA) are serine proteases that convert the circulating zymogen plasminogen to active plasmin and mediate fibrin degradation. These multifunctional proteins trigger various biological events such as extracellular matrix degradation, cell adhesion, migration, and proliferation, through not yet fully characterized mechanisms. We report that, in smooth muscle cells and ECV‐304 carcinoma cells, tPA and ATF (the N‐terminal catalytically inactive fragment of tPA) elicited DNA synthesis that requires activation of the sphingomyelin/ceramide/sphingosine‐1‐phosphate (Spm/Cer/S1P), signaling pathway and was blocked by D‐erythro‐2‐(N‐myristoylamino)‐1‐phenyl‐propanol (D‐MAPP) and N‐N’‐dimethyl sphingosine (DMS), two classical inhibitors of sphingosine‐1‐phosphate biosynthesis. Binding of tPA to its receptor uPAR triggered the coordinated activation of two key enzymes of the Spm/Cer/S1P pathway, the neutral sphingomyelinase and the sphingosine kinase‐1 that was mediated by a common pertussis toxin (PTX)‐sensitive mechanism. The tPA‐induced sphingosine kinase‐1 activation was mediated by Src, since it was inhibited by herbimycin A and in SrcK‐cells (overexpressing a dominant negative kinase defective form of Src) and by ERK1/2 (early phase peaking at 15 min). Sphingosine kinase‐1 activation was followed by a second phase of ERK1/2 phosphorylation (peaking at 120 min) and subsequent DNA synthesis, which were inhibited by D‐MAPP and DMS, by anti‐EGD‐1 antibodies and in SrcK‐cells (in which the mitogenic signaling was rescued by sphingosine‐1‐phosphate). Altogether, these data underline a pivotal role for the Spm/Cer/S1P pathway in the tPA‐induced mitogenic signaling.</description><subject>Benzoquinones</subject><subject>Cell Line</subject><subject>Cell Proliferation - drug effects</subject><subject>Ceramides - metabolism</subject><subject>Enzyme Activation - drug effects</subject><subject>Extracellular Signal-Regulated MAP Kinases - metabolism</subject><subject>Lactams, Macrocyclic</subject><subject>Lysophospholipids - pharmacology</subject><subject>MAP Kinase Signaling System - drug effects</subject><subject>Mitogens - pharmacology</subject><subject>Myocytes, Smooth Muscle - cytology</subject><subject>Myocytes, Smooth Muscle - drug effects</subject><subject>Myocytes, Smooth Muscle - enzymology</subject><subject>Myocytes, Smooth Muscle - metabolism</subject><subject>Peptide Fragments - chemistry</subject><subject>Peptide Fragments - pharmacology</subject><subject>Pertussis Toxin - pharmacology</subject><subject>Phosphorylation - drug effects</subject><subject>Phosphotransferases (Alcohol Group Acceptor) - metabolism</subject><subject>Quinones - pharmacology</subject><subject>Rifabutin - analogs &amp; derivatives</subject><subject>Signal Transduction - drug effects</subject><subject>Sphingomyelins - metabolism</subject><subject>Sphingosine - analogs &amp; derivatives</subject><subject>Sphingosine - pharmacology</subject><subject>sphingosine kinase</subject><subject>Src</subject><subject>Tissue Plasminogen Activator - pharmacology</subject><subject>tPA</subject><subject>Up-Regulation - drug effects</subject><subject>Urokinase-Type Plasminogen Activator - chemistry</subject><subject>Urokinase-Type Plasminogen Activator - genetics</subject><subject>Urokinase-Type Plasminogen Activator - pharmacology</subject><issn>0892-6638</issn><issn>1530-6860</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhi0EokvhyBX5xIl0x3biJNxKtVsolUClnCPXGXe9cuJgJ1ty4xH6EDwZT4JXuxI3Th7b33yj0U_IawZnDGq5NNszEBljXJgtPiELVgjIZCXhKVlAVfNMSlGdkBcxbgGAAZPPyQkruGAlzxfk9-0GaRw2tr_33YzO9kuNQXW2RTqocfOgZmojtf3Oux22qaCrm89syemw8anPh9mp0fr-HdXoHB2Cd9Ykw-FN9S2dvp7fUL_DgD-HgDGmj6RpJ510dzMdbYwT_vn1OM5DmulU7Gzv77GnSo92p0YfXpJnRrmIr47nKfm-Xt1efMyuv1x-uji_znQOcpUVWJYiz3VZ6Louc1GUvFQ1qyoOsigESpbrCpg20kgJslZlDlpXtSyYMLJS4pS8PXjTFj8mjGPT2bhfS_Xop9hIWXHOOCQwO4A6-BgDmmYItlNhbhg0-1gas21ANMdYEv_mKJ7uOmz_0cccEvD-ADxYh_P_bc362we-vgKxv6-vVuIvFfaeWg</recordid><startdate>200409</startdate><enddate>200409</enddate><creator>Maupas‐Schwalm, Françoise</creator><creator>Augé, Nathalie</creator><creator>Robinet, Catherine</creator><creator>Cambus, Jean‐Pierre</creator><creator>Parsons, Sarah J.</creator><creator>Salvayre, Robert</creator><creator>Nègre‐Salvayre, Anne</creator><general>Federation of American Societies for Experimental Biology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200409</creationdate><title>The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue‐type plasminogen activator</title><author>Maupas‐Schwalm, Françoise ; Augé, Nathalie ; Robinet, Catherine ; Cambus, Jean‐Pierre ; Parsons, Sarah J. ; Salvayre, Robert ; Nègre‐Salvayre, Anne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406E-5e77344c75c997435727a9188206553e614c801cf6f66069a740cc896513f68a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Benzoquinones</topic><topic>Cell Line</topic><topic>Cell Proliferation - drug effects</topic><topic>Ceramides - metabolism</topic><topic>Enzyme Activation - drug effects</topic><topic>Extracellular Signal-Regulated MAP Kinases - metabolism</topic><topic>Lactams, Macrocyclic</topic><topic>Lysophospholipids - pharmacology</topic><topic>MAP Kinase Signaling System - drug effects</topic><topic>Mitogens - pharmacology</topic><topic>Myocytes, Smooth Muscle - cytology</topic><topic>Myocytes, Smooth Muscle - drug effects</topic><topic>Myocytes, Smooth Muscle - enzymology</topic><topic>Myocytes, Smooth Muscle - metabolism</topic><topic>Peptide Fragments - chemistry</topic><topic>Peptide Fragments - pharmacology</topic><topic>Pertussis Toxin - pharmacology</topic><topic>Phosphorylation - drug effects</topic><topic>Phosphotransferases (Alcohol Group Acceptor) - metabolism</topic><topic>Quinones - pharmacology</topic><topic>Rifabutin - analogs &amp; derivatives</topic><topic>Signal Transduction - drug effects</topic><topic>Sphingomyelins - metabolism</topic><topic>Sphingosine - analogs &amp; derivatives</topic><topic>Sphingosine - pharmacology</topic><topic>sphingosine kinase</topic><topic>Src</topic><topic>Tissue Plasminogen Activator - pharmacology</topic><topic>tPA</topic><topic>Up-Regulation - drug effects</topic><topic>Urokinase-Type Plasminogen Activator - chemistry</topic><topic>Urokinase-Type Plasminogen Activator - genetics</topic><topic>Urokinase-Type Plasminogen Activator - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maupas‐Schwalm, Françoise</creatorcontrib><creatorcontrib>Augé, Nathalie</creatorcontrib><creatorcontrib>Robinet, Catherine</creatorcontrib><creatorcontrib>Cambus, Jean‐Pierre</creatorcontrib><creatorcontrib>Parsons, Sarah J.</creatorcontrib><creatorcontrib>Salvayre, Robert</creatorcontrib><creatorcontrib>Nègre‐Salvayre, Anne</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The FASEB journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maupas‐Schwalm, Françoise</au><au>Augé, Nathalie</au><au>Robinet, Catherine</au><au>Cambus, Jean‐Pierre</au><au>Parsons, Sarah J.</au><au>Salvayre, Robert</au><au>Nègre‐Salvayre, Anne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue‐type plasminogen activator</atitle><jtitle>The FASEB journal</jtitle><addtitle>FASEB J</addtitle><date>2004-09</date><risdate>2004</risdate><volume>18</volume><issue>12</issue><spage>1398</spage><epage>1400</epage><pages>1398-1400</pages><issn>0892-6638</issn><eissn>1530-6860</eissn><abstract>Plasminogen activators (tPA and uPA) are serine proteases that convert the circulating zymogen plasminogen to active plasmin and mediate fibrin degradation. These multifunctional proteins trigger various biological events such as extracellular matrix degradation, cell adhesion, migration, and proliferation, through not yet fully characterized mechanisms. We report that, in smooth muscle cells and ECV‐304 carcinoma cells, tPA and ATF (the N‐terminal catalytically inactive fragment of tPA) elicited DNA synthesis that requires activation of the sphingomyelin/ceramide/sphingosine‐1‐phosphate (Spm/Cer/S1P), signaling pathway and was blocked by D‐erythro‐2‐(N‐myristoylamino)‐1‐phenyl‐propanol (D‐MAPP) and N‐N’‐dimethyl sphingosine (DMS), two classical inhibitors of sphingosine‐1‐phosphate biosynthesis. Binding of tPA to its receptor uPAR triggered the coordinated activation of two key enzymes of the Spm/Cer/S1P pathway, the neutral sphingomyelinase and the sphingosine kinase‐1 that was mediated by a common pertussis toxin (PTX)‐sensitive mechanism. The tPA‐induced sphingosine kinase‐1 activation was mediated by Src, since it was inhibited by herbimycin A and in SrcK‐cells (overexpressing a dominant negative kinase defective form of Src) and by ERK1/2 (early phase peaking at 15 min). Sphingosine kinase‐1 activation was followed by a second phase of ERK1/2 phosphorylation (peaking at 120 min) and subsequent DNA synthesis, which were inhibited by D‐MAPP and DMS, by anti‐EGD‐1 antibodies and in SrcK‐cells (in which the mitogenic signaling was rescued by sphingosine‐1‐phosphate). Altogether, these data underline a pivotal role for the Spm/Cer/S1P pathway in the tPA‐induced mitogenic signaling.</abstract><cop>United States</cop><pub>Federation of American Societies for Experimental Biology</pub><pmid>15231724</pmid><doi>10.1096/fj.03-1123fje</doi><tpages>20</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0892-6638
ispartof The FASEB journal, 2004-09, Vol.18 (12), p.1398-1400
issn 0892-6638
1530-6860
language eng
recordid cdi_proquest_miscellaneous_66822120
source MEDLINE; Access via Wiley Online Library; Alma/SFX Local Collection
subjects Benzoquinones
Cell Line
Cell Proliferation - drug effects
Ceramides - metabolism
Enzyme Activation - drug effects
Extracellular Signal-Regulated MAP Kinases - metabolism
Lactams, Macrocyclic
Lysophospholipids - pharmacology
MAP Kinase Signaling System - drug effects
Mitogens - pharmacology
Myocytes, Smooth Muscle - cytology
Myocytes, Smooth Muscle - drug effects
Myocytes, Smooth Muscle - enzymology
Myocytes, Smooth Muscle - metabolism
Peptide Fragments - chemistry
Peptide Fragments - pharmacology
Pertussis Toxin - pharmacology
Phosphorylation - drug effects
Phosphotransferases (Alcohol Group Acceptor) - metabolism
Quinones - pharmacology
Rifabutin - analogs & derivatives
Signal Transduction - drug effects
Sphingomyelins - metabolism
Sphingosine - analogs & derivatives
Sphingosine - pharmacology
sphingosine kinase
Src
Tissue Plasminogen Activator - pharmacology
tPA
Up-Regulation - drug effects
Urokinase-Type Plasminogen Activator - chemistry
Urokinase-Type Plasminogen Activator - genetics
Urokinase-Type Plasminogen Activator - pharmacology
title The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue‐type plasminogen activator
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T18%3A40%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20sphingomyelin/ceramide%20pathway%20is%20involved%20in%20ERK1/2%20phosphorylation,%20cell%20proliferation,%20and%20uPAR%20overexpression%20induced%20by%20tissue%E2%80%90type%20plasminogen%20activator&rft.jtitle=The%20FASEB%20journal&rft.au=Maupas%E2%80%90Schwalm,%20Fran%C3%A7oise&rft.date=2004-09&rft.volume=18&rft.issue=12&rft.spage=1398&rft.epage=1400&rft.pages=1398-1400&rft.issn=0892-6638&rft.eissn=1530-6860&rft_id=info:doi/10.1096/fj.03-1123fje&rft_dat=%3Cproquest_cross%3E66822120%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66822120&rft_id=info:pmid/15231724&rfr_iscdi=true